RESUMEN
In heart transplantation, pulmonary hypertension and increased pulmonary vascular resistance followed by donor right ventricular dysfunction remain a major cause of perioperative morbidity and mortality. In lung transplantation, primary graft dysfunction remains a major obstacle because it can cause bronchiolitis obliterans and mortality. Pulmonary vasodilators have been used as an adjunct therapy for heart or lung transplantation, mainly to treat pulmonary hypertension, right ventricular failure, and associated refractory hypoxemia. Among pulmonary vasodilators, inhaled nitric oxide is unique in that it is selective in pulmonary circulation and causes fewer systemic complications such as hypotension, flushing, or coagulopathy. Nitric oxide is expected to prevent or attenuate primary graft dysfunction by decreasing ischemia-reperfusion injury in lung transplantation. However, when considering the long-term benefit of these medications, little evidence supports their use in heart or lung transplantation. Current guidelines endorse inhaled vasodilators for managing immediate postoperative right ventricular failure in lung or heart transplantation, but no guidance is offered regarding agent selection, dosing, or administration. This review presents the current evidence of inhaled nitric oxide in lung or heart transplantation as well as comparisons with other pulmonary vasodilators including cost differences in consideration of economic pressures to contain rising pharmacy costs.
Asunto(s)
Trasplante de Corazón/métodos , Trasplante de Pulmón/métodos , Vasodilatadores/administración & dosificación , Administración por Inhalación , Análisis Costo-Beneficio , Trasplante de Corazón/economía , Humanos , Hipertensión Pulmonar/tratamiento farmacológico , Hipertensión Pulmonar/etiología , Trasplante de Pulmón/economía , Óxido Nítrico/administración & dosificación , Óxido Nítrico/economía , Disfunción Primaria del Injerto/prevención & control , Circulación Pulmonar/efectos de los fármacos , Vasodilatadores/economía , Disfunción Ventricular Derecha/tratamiento farmacológico , Disfunción Ventricular Derecha/etiologíaRESUMEN
PURPOSE: Inhaled epoprostenol and inhaled nitric oxide are pulmonary vasodilators commonly used in the management of acute respiratory distress syndrome and right ventricular failure; however, they have vastly different cost profiles. The purpose of the project was to transition from nitric oxide to epoprostenol as the inhaled pulmonary vasodilator (IPV) of choice in adult critically ill patients and evaluate the effect of the transition on associated usage and costs. METHODS: A single-center, prospective, before and after quality improvement project including adult patients receiving inhaled nitric oxide, inhaled epoprostenol, or both was conducted in 7 adult intensive care units, operating rooms, and postanesthesia care units of a tertiary care academic medical center. The total number of patients, hours of therapy, and costs for each agent were compared between stages of protocol implementation and annually. RESULTS: Seven hundred twenty-nine patients received inhaled nitric oxide, inhaled epoprostenol, or both during the study period. The monthly inhaled nitric oxide use in number of patients, hours, and cost decreased during all stages of the project (p < 0.01). The monthly inhaled epoprostenol use in number of patients, hours, and cost increased during all stages (p < 0.01). Overall, total IPV use increased during the study. However, despite this increase in usage, there was a 47% reduction in total IPV cost. CONCLUSION: Implementation of a staged protocol to introduce and expand inhaled epoprostenol use in adult critically ill patients resulted in decreased use and cost of inhaled nitric oxide. The total cost of all IPV was decreased by 47% despite increased IPV use.
Asunto(s)
Epoprostenol/administración & dosificación , Óxido Nítrico/administración & dosificación , Mejoramiento de la Calidad/organización & administración , Síndrome de Dificultad Respiratoria/tratamiento farmacológico , Vasodilatadores/administración & dosificación , Administración por Inhalación , Adulto , Ahorro de Costo/economía , Ahorro de Costo/estadística & datos numéricos , Enfermedad Crítica/terapia , Costos de los Medicamentos/estadística & datos numéricos , Utilización de Medicamentos/economía , Utilización de Medicamentos/estadística & datos numéricos , Epoprostenol/economía , Implementación de Plan de Salud , Humanos , Pulmón/irrigación sanguínea , Pulmón/efectos de los fármacos , Óxido Nítrico/economía , Evaluación de Programas y Proyectos de Salud , Estudios Prospectivos , Mejoramiento de la Calidad/economía , Mejoramiento de la Calidad/estadística & datos numéricos , Síndrome de Dificultad Respiratoria/economíaRESUMEN
Pulmonary hypertension is one of the most challenging complications in congenital heart surgery. The purpose of this study was to characterize inhaled nitric oxide administration in children with and without pulmonary hypertension who underwent congenital heart surgery and to describe the effect of nitric oxide administration on admission outcomes. This is a cross-sectional study utilizing data from the Pediatric Health Information System (PHIS) and PHIS + databases from 2004 to 2015. Pediatric patients with a congenital heart disease diagnosis were included and divided into groups with pulmonary hypertension that received and not received inhaled nitric oxide and patients without diagnosis of pulmonary hypertension who received and did not receive inhaled nitric oxide. For all admissions, the following were captured: age of admission, gender, year of admission, length of stay, billed charges, inpatient mortality, the presence of specific congenital malformations of the heart, specific cardiac surgeries, and comorbidities. Comparisons between groups were completed using a Mann-Whitney-U test and Fisher's exact test. Outcomes evaluation was completed using univariate and regression analyses. A total of 40,194 pediatric cardiac surgical admissions without pulmonary hypertension were identified. Of these, 726 (1.8%) received inhaled nitric oxide. Regression analyses demonstrated that inhaled nitric oxide was independently associated with increased length of stay, billed charges, and inpatient mortality. A total of 1678 pediatric cardiac surgical admissions with pulmonary hypertension were identified. Of these, 195 (11.6%) received inhaled nitric oxide. Regression analyses demonstrated that inhaled nitric oxide was independently associated with a significant increase in length of stay and billed charges. There was no statistically significant association between inhaled nitric oxide and decrease mortality. Administration of inhaled nitric oxide after pediatric cardiac surgery increases length of stay and billed charges while not providing improved inpatient mortality. In fact, administration of inhaled nitric oxide was associated with increased mortality in those without pulmonary hypertension while not impacting mortality in any way in those with pulmonary hypertension.
Asunto(s)
Broncodilatadores/efectos adversos , Procedimientos Quirúrgicos Cardíacos/estadística & datos numéricos , Hipertensión Pulmonar/tratamiento farmacológico , Tiempo de Internación/estadística & datos numéricos , Óxido Nítrico/efectos adversos , Administración por Inhalación , Broncodilatadores/administración & dosificación , Broncodilatadores/economía , Procedimientos Quirúrgicos Cardíacos/economía , Estudios de Casos y Controles , Niño , Preescolar , Estudios Transversales , Femenino , Cardiopatías Congénitas/complicaciones , Cardiopatías Congénitas/mortalidad , Cardiopatías Congénitas/cirugía , Humanos , Hipertensión Pulmonar/complicaciones , Hipertensión Pulmonar/cirugía , Lactante , Masculino , Óxido Nítrico/administración & dosificación , Óxido Nítrico/economía , Periodo Posoperatorio , Resultado del TratamientoRESUMEN
Fractional exhaled nitric oxide (FeNO) is the only available point of care test to assess type-2 inflammation in asthma. In making a diagnosis of asthma, FeNO should be used together with blood eosinophils and spirometry, alongside a history. Raised FeNO in conjunction with blood eosinophilia are treatable traits of type 2 inflammation in asthma, which in turn may guide personalised management. A FeNO suppression test can be used to assess adherence and device use with ICS therapy. Furthermore FeNO may be used to provide feedback to patients in response to ICS, especially when spirometry is normal. FeNO may facilitate appropriate referral to secondary care for more definitive specialist investigations. In summary, FeNO is cost effective in the diagnosis and management of asthma and should be incorporated into primary and secondary care as part of routine clinical practice.
Asunto(s)
Asma/sangre , Asma/tratamiento farmacológico , Inflamación/metabolismo , Óxido Nítrico/análisis , Corticoesteroides/administración & dosificación , Corticoesteroides/uso terapéutico , Agonistas Adrenérgicos beta/uso terapéutico , Asma/diagnóstico , Asma/fisiopatología , Eosinófilos , Espiración/fisiología , Humanos , Inflamación/clasificación , Cumplimiento de la Medicación/psicología , Nebulizadores y Vaporizadores/normas , Óxido Nítrico/economía , Atención Primaria de Salud/normas , Escocia/epidemiología , Espirometría/métodosRESUMEN
Right ventricular (RV) failure is a potentially fatal complication following heart transplantation (HTx). Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator that is used to decrease pulmonary vascular resistance immediately post-HTx to reduce the risk of RV failure. The aim of this study was to describe utilization patterns, costs, and outcomes associated with post-transplant iNO use in children. All pediatric HTx recipients (2002-2016) were identified from a unique linked PHIS/SRTR dataset. Post-HTx iNO use was determined based on hospital billing data. Utilization patterns and associated costs were described. The association of iNO support with post-HTx survival was assessed using the Kaplan-Meier method and a multivariable Cox proportional hazards model was used to adjust for risk factors. A total of 2833 pediatric HTx recipients from 28 centers were identified with 1057 (36.5%) receiving iNO post-HTx. Post-HTx iNO use showed significant increase overall (17.2-54.7%, p < 0.001) and wide variation among centers (9-100%, p < 0.001). Patients with congenital heart disease (aOR 1.4, 95% CI 1.2, 1.6), requiring mechanical ventilation at HTx (aOR 1.3, 95% CI 1.1, 1.6), and pre-transplant iNO (aOR 9.3, 95% CI 5.4, 16) were more likely to receive iNO post-HTx. The median daily cost of iNO was $2617 (IQR $1843-$3646). Patients who required > 5 days of iNO post-HTx demonstrated inferior 1-year post-HTx survival (p < 0.001) and iNO use > 5 days was independently associated with worse post-HTx survival (AHR 1.6, 95% CI 1.2, 2.1; p < 0.001). There is wide variation in iNO use among centers following pediatric HTx with use increasing over time despite significant incremental cost. Prolonged iNO use post-HTx is associated with worse survival, likely serving as a marker of residual illness severity. Further research is needed to define the populations that derive the greatest benefit from this costly therapy.
Asunto(s)
Costos de la Atención en Salud/estadística & datos numéricos , Trasplante de Corazón/efectos adversos , Óxido Nítrico/administración & dosificación , Pautas de la Práctica en Medicina/estadística & datos numéricos , Vasodilatadores/administración & dosificación , Administración por Inhalación , Adolescente , Niño , Preescolar , Femenino , Trasplante de Corazón/mortalidad , Trasplante de Corazón/estadística & datos numéricos , Humanos , Lactante , Masculino , Óxido Nítrico/economía , Pautas de la Práctica en Medicina/economía , Modelos de Riesgos Proporcionales , Sistema de Registros , Estudios Retrospectivos , Factores de Riesgo , Análisis de Supervivencia , Resultado del Tratamiento , Vasodilatadores/economíaRESUMEN
Topical antimicrobials are the ideal mode of onychomycosis treatment for efficient drug delivery and avoidance of sytemic effects associated with oral medications. However, high treatment costs, tissue penetration limitations, and low cure rates have continued to pose major challenges. To capitalize on the progress made by topical efinaconazole solution, efinaconazole was combined with inexpensive, previously-characterized nitric oxide releasing nanoparticles (NO-np), which have been shown to offer sustained nitric oxide release over time and enhanced barrier penetration, while exerting broad spectrum antimicrobial and immunomodulating properties. NO-np were combined with efinaconazole in varying concentrations and applied against reference strains of Trichophyton rubrum using a checkerboard method. Results demonstrated synergism of NO-np+efinaconazole against T. rubrum, which is noteworthy given the barriers present in the topical treatment of onychomycosis, and the multiple potential benefits offered by NO-np. Overall, this study illustrates the untapped potential of nanotechnology in the treatment of disorders of the skin, hair, and nails where drug delivery remains a challenge. J Drugs Dermatol. 2018;17(7):717-720.
Asunto(s)
Antifúngicos/uso terapéutico , Portadores de Fármacos/química , Onicomicosis/tratamiento farmacológico , Trichophyton/efectos de los fármacos , Administración Tópica , Animales , Antifúngicos/economía , Antifúngicos/farmacología , Modelos Animales de Enfermedad , Liberación de Fármacos , Sinergismo Farmacológico , Quimioterapia Combinada/economía , Quimioterapia Combinada/métodos , Humanos , Ratones , Pruebas de Sensibilidad Microbiana , Nanopartículas/química , Naftalenos/economía , Naftalenos/uso terapéutico , Óxido Nítrico/economía , Óxido Nítrico/farmacología , Óxido Nítrico/uso terapéutico , Onicomicosis/microbiología , Permeabilidad , Honorarios por Prescripción de Medicamentos , Terbinafina , Resultado del Tratamiento , Triazoles/economía , Triazoles/farmacología , Triazoles/uso terapéuticoAsunto(s)
Anestesia en Procedimientos Quirúrgicos Cardíacos/métodos , Procedimientos Quirúrgicos Cardíacos/métodos , Análisis Costo-Beneficio/métodos , Epoprostenol/administración & dosificación , Medicina Basada en la Evidencia/métodos , Óxido Nítrico/administración & dosificación , Administración por Inhalación , Anestesia en Procedimientos Quirúrgicos Cardíacos/economía , Antihipertensivos/administración & dosificación , Antihipertensivos/economía , Procedimientos Quirúrgicos Cardíacos/economía , Factores Relajantes Endotelio-Dependientes/administración & dosificación , Factores Relajantes Endotelio-Dependientes/economía , Epoprostenol/economía , Medicina Basada en la Evidencia/economía , Humanos , Óxido Nítrico/economía , Ensayos Clínicos Controlados Aleatorios como Asunto/métodosRESUMEN
El óxido nítrico inhalatorio (ONi) es actualmente la terapia de primera línea en la insuficiencia respiratoria hipoxémica grave del recién nacido; la mayor parte de los centros neonatales de regiones en Chile no cuentan con esta alternativa terapéutica. Objetivo: Determinar el costo-efectividad del ONi en el tratamiento de la insuficiencia respiratoria asociada a hipertensión pulmonar del recién nacido, comparado con el cuidado habitual y el traslado a un centro de mayor complejidad. Pacientes y método: Se modeló un árbol de decisiones clínicas desde la perspectiva del sistema de salud público chileno, se calcularon razones de costo-efectividad incremental (ICER), se realizó análisis de sensibilidad determinístico y probabilístico, se estimó el impacto presupuestario, software: TreeAge Health Care Pro 2014. Resultados: La alternativa ONi produce un aumento promedio en los costos de 11,7 millones de pesos por paciente tratado, con una razón de costo-efectividad incremental comparado con el cuidado habitual de 23 millones de pesos por muerte o caso de oxigenación extracorpórea evitada. Al sensibilizar los resultados por incidencia, encontramos que a partir de 7 casos tratados al año resulta menos costoso el óxido nítrico que el traslado a un centro de mayor complejidad. Conclusiones: Desde la perspectiva de un hospital regional chileno incorporar ONi en el manejo de la insuficiencia respiratoria neonatal resulta la alternativa óptima en la mayoría de los escenarios posibles.
Inhaled nitric oxide (iNO) is currently the first-line therapy in severe hypoxaemic respiratory failure of the newborn. Most of regional neonatal centres in Chile do not have this therapeutic alternative. Objective: To determine the cost effectiveness of inhaled nitric oxide in the treatment of respiratory failure associated with pulmonary hypertension of the newborn compared to the usual care, including the transfer to a more complex unit. Patients and method: A clinical decision tree was designed from the perspective of Chilean Public Health Service. Incremental cost effectiveness rates (ICER) were calculated, deterministic sensitivity analysis was performed, and probabilistic budget impact was estimated using: TreeAge Pro Healthcare 2014 software. Results: The iNO option leads to an increase in mean cost of $ 11.7 million Chilean pesos ( 15,000) per patient treated, with an ICER compared with the usual care of $ 23 million pesos ( 30,000) in case of death or ECMO avoided. By sensitising the results by incidence, it was found that from 7 cases and upwards treated annually, inhaled nitric oxide is less costly than the transfer to a more complex unit. Conclusions: From the perspective of a Chilean regional hospital, incorporating inhaled nitric oxide into the management of neonatal respiratory failure is the optimal alternative in most scenarios.
Asunto(s)
Humanos , Recién Nacido , Insuficiencia Respiratoria/tratamiento farmacológico , Broncodilatadores/administración & dosificación , Hipertensión Pulmonar/complicaciones , Óxido Nítrico/administración & dosificación , Insuficiencia Respiratoria/economía , Insuficiencia Respiratoria/etiología , Administración por Inhalación , Broncodilatadores/economía , Presupuestos , Árboles de Decisión , Chile , Salud Pública/economía , Transferencia de Pacientes/economía , Análisis Costo-Beneficio , Hospitalización/economía , Neonatología/economía , Óxido Nítrico/economíaRESUMEN
Inhaled nitric oxide (iNO) is currently the first-line therapy in severe hypoxaemic respiratory failure of the newborn. Most of regional neonatal centres in Chile do not have this therapeutic alternative. OBJECTIVE: To determine the cost effectiveness of inhaled nitric oxide in the treatment of respiratory failure associated with pulmonary hypertension of the newborn compared to the usual care, including the transfer to a more complex unit. PATIENTS AND METHOD: A clinical decision tree was designed from the perspective of Chilean Public Health Service. Incremental cost effectiveness rates (ICER) were calculated, deterministic sensitivity analysis was performed, and probabilistic budget impact was estimated using: TreeAge Pro Healthcare 2014 software. RESULTS: The iNO option leads to an increase in mean cost of $ 11.7 million Chilean pesos (15,000) per patient treated, with an ICER compared with the usual care of $23 million pesos (30,000) in case of death or ECMO avoided. By sensitising the results by incidence, it was found that from 7 cases and upwards treated annually, inhaled nitric oxide is less costly than the transfer to a more complex unit. CONCLUSIONS: From the perspective of a Chilean regional hospital, incorporating inhaled nitric oxide into the management of neonatal respiratory failure is the optimal alternative in most scenarios.
Asunto(s)
Broncodilatadores/administración & dosificación , Hipertensión Pulmonar/complicaciones , Óxido Nítrico/administración & dosificación , Insuficiencia Respiratoria/tratamiento farmacológico , Administración por Inhalación , Broncodilatadores/economía , Presupuestos , Chile , Análisis Costo-Beneficio , Árboles de Decisión , Hospitalización/economía , Humanos , Recién Nacido , Neonatología/economía , Óxido Nítrico/economía , Transferencia de Pacientes/economía , Salud Pública/economía , Insuficiencia Respiratoria/economía , Insuficiencia Respiratoria/etiologíaRESUMEN
OBJECTIVES: To evaluate the effect of inhaled nitric oxide on outcomes in children with acute lung injury. DESIGN: Retrospective study with a secondary data analysis of linked data from two national databases. Propensity score matching was performed to adjust for potential confounding variables between patients who received at least 24 hours of inhaled nitric oxide (inhaled nitric oxide group) and those who did not receive inhaled nitric oxide (no inhaled nitric oxide group). SETTING: Linked data from Virtual Pediatric Systems (LLC) database and Pediatric Health Information System. PATIENTS: Patients less than 18 years old receiving mechanical ventilation for acute lung injury at nine participating hospitals were included (2009-2014). INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A total of 20,106 patients from nine hospitals were included. Of these, 859 patients (4.3%) received inhaled nitric oxide for at least 24 hours during their hospital stay. Prior to matching, patients in the inhaled nitric oxide group were younger, with more comorbidities, greater severity of illness scores, higher prevalence of cardiopulmonary resuscitation, and greater resource utilization. Before matching, unadjusted outcomes, including mortality, were worse in the inhaled nitric oxide group (inhaled nitric oxide vs no inhaled nitric oxide; 25.7% vs 7.9%; p < 0.001; standardized mortality ratio, 2.6 [2.3-3.1] vs 1.1 [1.0-1.2]; p < 0.001). Propensity score matching of 521 patient pairs revealed no difference in mortality in the two groups (22.3% vs 20.2%; p = 0.40; standardized mortality ratio, 2.5 [2.1-3.0] vs 2.3 [1.9-2.8]; p = 0.53). However, the other outcomes such as ventilation free days (10.1 vs 13.6 d; p < 0.001), duration of mechanical ventilation (13.8 vs 10.1 d; p < 0.001), duration of ICU and hospital stay (15.5 vs 12.2 d; p < 0.001 and 28.0 vs 24.1 d; p < 0.001), and hospital costs ($150,569 vs $102,823; p < 0.001) were significantly worse in the inhaled nitric oxide group. CONCLUSIONS: This large observational study demonstrated that inhaled nitric oxide administration in children with acute lung injury was not associated with improved mortality. Rather, it was associated with increased hospital utilization and hospital costs.
Asunto(s)
Lesión Pulmonar Aguda/mortalidad , Lesión Pulmonar Aguda/terapia , Óxido Nítrico/administración & dosificación , Respiración Artificial/métodos , Lesión Pulmonar Aguda/tratamiento farmacológico , Adolescente , Factores de Edad , Niño , Preescolar , Comorbilidad , Femenino , Costos de Hospital , Humanos , Lactante , Masculino , Óxido Nítrico/economía , Puntaje de Propensión , Estudios Retrospectivos , Índice de Severidad de la EnfermedadAsunto(s)
Cuidado Intensivo Neonatal/economía , Óxido Nítrico/administración & dosificación , Administración por Inhalación , Costos y Análisis de Costo , Humanos , Hipoxia/economía , Hipoxia/terapia , Recién Nacido , Enfermedades del Prematuro/economía , Enfermedades del Prematuro/terapia , Unidades de Cuidado Intensivo Neonatal , Óxido Nítrico/economía , Insuficiencia Respiratoria/economía , Insuficiencia Respiratoria/terapiaRESUMEN
BACKGROUND: Direct comparisons of inhaled nitric oxide (iNO) to inhaled epoprostenol (iEPO) in patients with acute pulmonary hypertension (PHT) following cardiac surgery are lacking. OBJECTIVE: To compare the relative efficacy, safety, and cost of iNO versus iEPO in patients with acute PHT following cardiac surgery. METHODS: This is a single-center, retrospective, observational, cohort study comparing iNO to iEPO for acute postoperative PHT following cardiac surgery. The primary outcome was reduction of mean pulmonary artery pressure (mPAP) to < 30 mm Hg, 6 hours after ICU admission from the operating room. Secondary outcomes, included ICU and hospital length of stay, duration of mechanical ventilation, bleeding complications, hypotension, in-hospital mortality, and cost. RESULTS: A total of 98 patients met inclusion criteria (iNO, n = 49; iEPO, n = 49). There was no difference in the primary outcome of reduction of mPAP to < 30 mm Hg 6 hours after ICU admission (iNO, 33 [67%] vs iEPO, 35 [71%]; P = 0.83) or in the incidence of adverse events collected (iNO, 10 [20%] vs iEPO, 11 [22%]; P = 1.00). Based on cost estimates, the median cost of iEPO per patient was $363.53 ($226-$864.60) versus $2562.50 ($1875-$8625) for iNO (P < 0.01). CONCLUSIONS: The relative efficacy of iEPO appeared to be similar to that of iNO in reducing mPAP following cardiac surgery, in this retrospective review. Significant cost savings were associated with the use of iEPO.
Asunto(s)
Procedimientos Quirúrgicos Cardíacos/efectos adversos , Epoprostenol/administración & dosificación , Hipertensión Pulmonar/tratamiento farmacológico , Óxido Nítrico/administración & dosificación , Vasodilatadores/administración & dosificación , Administración por Inhalación , Adulto , Anciano , Presión Sanguínea/efectos de los fármacos , Estudios de Cohortes , Epoprostenol/economía , Femenino , Hemorragia/prevención & control , Mortalidad Hospitalaria , Humanos , Hipertensión/complicaciones , Hipertensión Pulmonar/economía , Hipertensión Pulmonar/fisiopatología , Tiempo de Internación , Masculino , Persona de Mediana Edad , Óxido Nítrico/economía , Respiración Artificial , Estudios Retrospectivos , Vasodilatadores/economíaRESUMEN
OBJECTIVE: We reported recently that early use of inhaled nitric oxide therapy (iNO) for term and late preterm infants with hypoxic respiratory failure (HRF) at an oxygenation index (OI) of ≥15 and <20 is associated with earlier discharge from the hospital, relative to babies treated at OI ≥25. The objective of the present analysis is to determine whether earlier use of iNO in this cohort leads to lower cost of medical care. METHODS: We used a decision-analytic model, which was developed to compare hospital resource use and costs associated with early versus standard use of iNO in HRF. The model population included infants with moderate HRF caused by primary pulmonary hypertension with an OI ≥15 and <20. A hypothetical case population of 1000 patients was assumed and probabilistic sensitivity analyses were completed where all the clinical inputs into the model were varied. Two deterministic sensitivity analyses were also completed, one surrounding the hospital cost inputs and another surrounding the cost of iNO. RESULTS: Early iNO was associated with fewer hospital days, fewer days of ventilation and fewer hours on extracorporeal membrane oxygenation (ECMO). In probabilistic sensitivity analyses, total costs per patient were $88,518 ± $7574 and $92,581 ± $9664 for early iNO and standard iNO, respectively. The probability of early iNO being cost-effective was approximately 72%, based on a willingness to pay $100,000 or less to prevent ECMO therapy and/or death. In both deterministic sensitivity analyses, early iNO was cost-saving. CONCLUSION: Our analysis shows that early use of iNO at an OI of ≥15 and <20 may be associated with shorter hospitalizations and a decreased cost of care for term/late preterm infants with HRF associated with pulmonary hypertension. Our results are based on clinical data from a single trial; future research using data from real-world practice is warranted.
Asunto(s)
Óxido Nítrico/administración & dosificación , Óxido Nítrico/economía , Insuficiencia Respiratoria/tratamiento farmacológico , Vasodilatadores/administración & dosificación , Vasodilatadores/economía , Administración por Inhalación , Oxigenación por Membrana Extracorpórea/estadística & datos numéricos , Femenino , Precios de Hospital/estadística & datos numéricos , Humanos , Hipertensión Pulmonar/complicaciones , Recién Nacido , Tiempo de Internación/estadística & datos numéricos , Masculino , Modelos Econométricos , Reproducibilidad de los Resultados , Respiración Artificial/estadística & datos numéricos , Insuficiencia Respiratoria/etiologíaRESUMEN
BACKGROUND: The objective of this study was to determine whether the implementation of an inhaled nitric oxide protocol (INO) in a pediatric ICU (PICU) would reduce cost associated with its use without negatively affecting patient outcomes. METHODS: This is a retrospective cohort study of 76 subjects who required INO therapy in the PICU during the study period. A nitric oxide setup and weaning protocol was implemented in the PICU. The medical records of subjects who had received INO 18 months after protocol implementation, as well as the medical records of subjects who had received INO in the 18 months before protocol implementation, were reviewed. Length of time on INO, cost of INO per subject, mortality, stay, and ventilator hours were recorded. RESULTS: There were 38 subjects in the pre-protocol group and 38 subjects in the post-protocol group. There was a statistically significant decrease in the median per subject cost of INO between the pre- and post-protocol groups (P < .01). There was no statistically significant difference in the median duration of INO use (P = .06), median PICU (P = .42) or hospital (P = .58) stay, median duration of mechanical ventilation (P = .79) or percent mortality (P = .28) between the 2 groups. CONCLUSIONS: Implementation of an INO setup and weaning protocol in a PICU reduces the cost associated with its use without a statistically significant difference in mortality. In an era of increased awareness regarding healthcare spending, implementation of evidence-based protocols can provide a way to ensure the judicious utilization of medical resources.
Asunto(s)
Broncodilatadores/economía , Protocolos Clínicos/normas , Costos Directos de Servicios/estadística & datos numéricos , Unidades de Cuidado Intensivo Pediátrico/economía , Óxido Nítrico/economía , Administración por Inhalación , Adolescente , Broncodilatadores/administración & dosificación , Niño , Preescolar , Femenino , Mortalidad Hospitalaria/tendencias , Humanos , Lactante , Recién Nacido , Unidades de Cuidado Intensivo Pediátrico/normas , Unidades de Cuidado Intensivo Pediátrico/estadística & datos numéricos , Tiempo de Internación , Masculino , Óxido Nítrico/administración & dosificación , Respiración Artificial/estadística & datos numéricos , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
BACKGROUND AND OBJECTIVE: Decreasing practice variation and following clinical guidelines improve patient outcomes and reduce costs. Inhaled nitric oxide (iNO) is an effective but expensive treatment of pulmonary hypertension and right heart failure in patients with congenital or acquired heart disease. Our objective was to implement standardized initiation and weaning guidelines for iNO usage in the cardiothoracic ICU (CTICU) to reduce variation in use while maintaining quality patient care. METHODS: All CTICU patients who received iNO from January 2011 to December 2012 were retrospectively reviewed. Standardized iNO initiation and weaning guidelines were implemented in January 2012. Variables before and after guideline implementation were compared. RESULTS: From January to December 2011, there were 36 separate iNO events (6% of CTICU admissions; n = 547). Mean ± SD iNO usage per event was 159 ± 177 hours (median: 63 hours; range: 27-661 hours). From January to December 2012, there were 47 separate iNO events (8% of CTICU admissions; n = 554). Mean iNO usage per event was 125 ± 134 hours (median: 72 hours; range: 2-557 hours). Initiation guideline compliance improved from 83% to 86% (P = .9); weaning guideline compliance improved from 17% to 79% (P < .001). Although mean iNO usage per event decreased, there was no significant reduction in utilization of iNO (P = .09). CONCLUSIONS: Implementation of standardized iNO initiation and weaning guidelines in the CTICU was successful in reducing practice variation supported by increasing guideline compliance. However, decreasing practice variation did not significantly reduce iNO utilization and does not necessarily reduce cost.
Asunto(s)
Cardiopatías Congénitas/tratamiento farmacológico , Insuficiencia Cardíaca/tratamiento farmacológico , Hipertensión Pulmonar/tratamiento farmacológico , Óxido Nítrico/administración & dosificación , Pautas de la Práctica en Medicina/normas , Mejoramiento de la Calidad/normas , Administración por Inhalación , Adolescente , Niño , Preescolar , Ahorro de Costo , Esquema de Medicación , Femenino , Adhesión a Directriz/economía , Adhesión a Directriz/normas , Cardiopatías Congénitas/economía , Insuficiencia Cardíaca/economía , Hospitales Pediátricos , Humanos , Hipertensión Pulmonar/economía , Lactante , Recién Nacido , Unidades de Cuidado Intensivo Pediátrico/economía , Unidades de Cuidado Intensivo Pediátrico/normas , Masculino , Óxido Nítrico/economía , Ohio , Pautas de la Práctica en Medicina/economía , Mejoramiento de la Calidad/economía , Estudios Retrospectivos , Revisión de Utilización de RecursosRESUMEN
Decreases in endothelial nitric oxide synthase derived nitric oxide (NO) production during liver transplantation promotes injury. We hypothesized that preemptive inhaled NO (iNO) would improve allograft function (primary) and reduce complications post-transplantation (secondary). Patients at two university centers (Center A and B) were randomized to receive placebo (nâ=â20/center) or iNO (80 ppm, nâ=â20/center) during the operative phase of liver transplantation. Data were analyzed at set intervals for up to 9-months post-transplantation and compared between groups. Patient characteristics and outcomes were examined with the Mann-Whitney U test, Student t-test, logistic regression, repeated measures ANOVA, and Cox proportional hazards models. Combined and site stratified analyses were performed. MELD scores were significantly higher at Center B (22.5 vs. 19.5, p<0.0001), surgical times were greater at Center B (7.7 vs. 4.5 hrs, p<0.001) and warm ischemia times were greater at Center B (95.4 vs. 69.7 min, p<0.0001). No adverse metabolic or hematologic effects from iNO occurred. iNO enhanced allograft function indexed by liver function tests (Center B, p<0.05; and p<0.03 for ALT with center data combined) and reduced complications at 9-months (Center A and B, pâ=â0.0062, ORâ=â0.15, 95% CI (0.04, 0.59)). ICU (pâ=â0.47) and hospital length of stay (pâ=â0.49) were not decreased. iNO increased concentrations of nitrate (p<0.001), nitrite (p<0.001) and nitrosylhemoglobin (p<0.001), with nitrite being postulated as a protective mechanism. Mean costs of iNO were $1,020 per transplant. iNO was safe and improved allograft function at one center and trended toward improving allograft function at the other. ClinicalTrials.gov with registry number 00582010 and the following URL:http://clinicaltrials.gov/show/NCT00582010.
Asunto(s)
Antiinflamatorios/administración & dosificación , Fallo Hepático/cirugía , Trasplante de Hígado/métodos , Óxido Nítrico/administración & dosificación , Adulto , Anciano , Aloinjertos , Análisis de Varianza , Estudios de Cohortes , Transfusión de Eritrocitos , Femenino , Costos de la Atención en Salud , Humanos , Inflamación/tratamiento farmacológico , Unidades de Cuidados Intensivos , Tiempo de Internación , Masculino , Persona de Mediana Edad , Óxido Nítrico/economía , Transfusión de Plaquetas , Modelos de Riesgos Proporcionales , Resultado del TratamientoRESUMEN
Nitric oxide, an important signaling molecule with multiple regulatory effects throughout the body, is an important tool for the treatment of full-term and late-preterm infants with persistent pulmonary hypertension of the newborn and hypoxemic respiratory failure. Several randomized controlled trials have evaluated its role in the management of preterm infants ≤ 34 weeks' gestational age with varying results. The purpose of this clinical report is to summarize the existing evidence for the use of inhaled nitric oxide in preterm infants and provide guidance regarding its use in this population.
Asunto(s)
Broncodilatadores/uso terapéutico , Enfermedades del Prematuro/tratamiento farmacológico , Óxido Nítrico/uso terapéutico , Síndrome de Circulación Fetal Persistente/tratamiento farmacológico , Insuficiencia Respiratoria/tratamiento farmacológico , Administración por Inhalación , Broncodilatadores/economía , Análisis Costo-Beneficio , Esquema de Medicación , Humanos , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro/economía , Óxido Nítrico/economía , Síndrome de Circulación Fetal Persistente/economía , Insuficiencia Respiratoria/economía , Resultado del Tratamiento , Estados UnidosRESUMEN
PURPOSE: The purpose of this is to compare efficacy, safety, and cost outcomes in patients who have received either inhaled epoprostenol (iEPO) or inhaled nitric oxide (iNO) for hypoxic respiratory failure. MATERIALS AND METHODS: This is a retrospective, single-center analysis of adult, mechanically ventilated patients receiving iNO or iEPO for improvement in oxygenation. RESULTS: We evaluated 105 mechanically ventilated patients who received iEPO (52 patients) or iNO (53 patients) between January 2009 and October 2010. Most patients received therapy for acute respiratory distress syndrome (iNO 58.5% vs iEPO 61.5%; P=.84). There was no difference in the change in the partial pressure of arterial O2/fraction of inspired O2 ratio after 1 hour of therapy (20.58±91.54 vs 33.04±36.19 [P=.36]) in the iNO and iEPO groups, respectively. No difference was observed in duration of therapy (P=.63), mechanical ventilation (P=.07), intensive care unit (P=.67), and hospital lengths of stay (P=.26) comparing the iNO and iEPO groups. No adverse events were attributed to either therapy. Inhaled nitric oxide was 4.5 to 17 times more expensive than iEPO depending on contract pricing. CONCLUSIONS: We found no difference in efficacy and safety outcomes when comparing iNO and iEPO in hypoxic, critically ill patients. Inhaled epoprostenol is associated with less drug expenditure than iNO.
Asunto(s)
Antihipertensivos/administración & dosificación , Broncodilatadores/administración & dosificación , Enfermedad Crítica , Epoprostenol/administración & dosificación , Hipoxia/tratamiento farmacológico , Óxido Nítrico/administración & dosificación , APACHE , Administración por Inhalación , Antihipertensivos/economía , Broncodilatadores/economía , Comorbilidad , Epoprostenol/economía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Óxido Nítrico/economía , Respiración Artificial , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
OBJECTIVE: The purpose of this study was to determine the cost-effectiveness of early versus late inhaled nitric oxide (INO) therapy in neonates with hypoxic respiratory failure initially managed on conventional mechanical ventilation. RESEARCH DESIGN: A decision analytic model was created to compare the use of early INO compared to delayed INO for neonates receiving mechanical ventilation due to hypoxic respiratory failure. The perspective of the model was that of a hospital. Patients who did not respond to either early or delayed INO were assumed to have been treated with extracorporeal membrane oxygenation (ECMO). The effectiveness measure was defined as a neonate discharged alive without requiring ECMO therapy. A Monte Carlo simulation of 10,000 cases was conducted using first and second order probabilistic analysis. Direct medical costs that differed between early versus delayed INO treatment were estimated until time to hospital discharge. The proportion of successfully treated patients and costs were determined from the probabilistic sensitivity analysis. RESULTS: The mean (± SD) effectiveness rate for early INO was 0.75 (± 0.08) and 0.61 (± 0.09) for delayed INO. The mean hospital cost for early INO was $21,462 (± $2695) and $27,226 (± $3532) for delayed INO. In 87% of scenarios, early INO dominated delayed INO by being both more effective and less costly. The acceptability curve between products demonstrated that early INO had over a 90% probability of being the most cost-effective treatment across a wide range of willingness to pay values. CONCLUSIONS: This analysis indicated that early INO therapy was cost-effective in neonates with hypoxic respiratory failure requiring mechanical ventilation compared to delayed INO by reducing the probability of developing severe hypoxic respiratory failure. There was a 90% or higher probability that early INO was more cost-effective than delayed INO across a wide range of willingness to pay values in this analysis.